Table 1 Included studies

Annemans et al. 2006 [8]

At risk of cardiovascular disease (primary prevention)

ASA

· MI

Payer

10 years

· Stroke

Berg et al. 2007 [9]

STEMI

Clopidogrel + ASA

· MI

Societal

1 year

· Stroke

Berg et al. 2008 [10]

ACS undergoing PCI

Clopidogrel + ASA

· MI

Payer

Not specified

· Stroke

Berger et al. 2008 [11]

Elevated risk of MI, ischaemic stroke

Clopidogrel

· MI

Payer

2 years

· Stroke

Brüggenjürgen et al. 2007 [12]

ACS without ST-elevation

Clopidogrel + ASA

· MI

Payer

Lifetime

· Stroke

Claes et al. 2008 [13]

Stroke

Dipyridamole + ASA

· Stroke

Payer

Lifetime

Gandjour et al. 2007 [14]

Hypertension at high or low risk for CVD

National hypertension treatment programme

· MI

Payer

Lifetime

· Stroke

Jürgensen et al. 2009 [15]

Dialysis

Immunosuppressive therapy – sirolimus

· End-stage renal disease

Payer

2 years

Lamotte et al. 2006 [16]

CVD

ASA

· MI

Payer

10 years

· Stroke

Lamotte et al. 2006 [17]

MI

n-3 PUFA post-MI

· MI

Payer

3.5 years

· Stroke

Liebl et al. 2006 [18]

IGT

Acarbose

· Angina pectoris

Payer

3.3 years

· Heart failure

· MI

· Stroke

Mittendorf et al. 2009 [19]

Type 2 DM

Exenatide

· Angina pectoris

Payer

10 years

· Blindness

· Cataract

· Diabetic foot syndrome

· End-stage renal disease

· Heart failure

· MI

· Neuropathy

· Retinopathy

· Stroke

Neeser et al. 2006 [20]

Atrial fibrillation

Oral vitamin K antagonists

· Stroke

Not specified

10 years

Rasch et al. 2009 [21]

Smoking

Varenicline

· Stroke

Payer

Lifetime

Rosery et al. 2006 [22]

Secondary hyperparathyroidism during haemodialysis

Paricalcitol (i.v.)

· End-stage renal disease

Payer

1 year

Roze et al. 2006 [23]

Insulin-naïve type 2 DM

Acarbose + diet

· Angina pectoris

Payer

35 years

· Blindness

· Cataract

· Diabetic foot syndrome

· End-stage renal disease

· Heart failure

· MI

· Neuropathy

· Stroke

Schaufler 2009 [24]

Type 2 DM

Type 2 DM prevention

· Blindness

Payer

1 year

· Diabetic foot syndrome

· End-stage renal disease

· MI

· Retinopathy

· Stroke

Scherbaum et al. 2009 [25]

Type 2 DM with macrovascular disease

Pioglitazone

· Blindness

Payer

35 years

· Cataract

· Diabetic foot syndrome

· End-stage renal disease

· Heart failure

· MI

· Neuropathy

· Retinopathy

· Stroke

Schwander et al. 2009 [26]

CVD

Eprosartan

· Angina pectoris

Payer

Lifetime

· MI

· Stroke

Valentine et al. 2008 [27]

Type 2 DM

Insulin detemir ± oral antidiabetic agents

· Angina pectoris

Payer

35 years

· Blindness

· Cataract

· Diabetic foot syndrome

· End-stage renal disease

· Heart failure

· MI

· Neuropathy

· Stroke

Weber et al. 2007 [28]

Type 2 DM

Self-measurement of blood glucose

· Blindness

Payer

8 years

· Cataract

· Diabetic foot syndrome

· End-stage renal disease

· Heart failure

· MI

· Neuropathy

· Retinopathy

· Stroke